Sanofi
French multinational pharmaceutical and healthcare company
Follow Sanofi on Notably News to receive short updates to your email — rarely!
| 2024 | Acquisition of Inhibrx |
| October 2024 | Sanofi and CD&R entered exclusive negotiations to transfer a 50% controlling stake in Opella, with Sanofi remaining a significant shareholder. |
| January 2024 | Sanofi announced an agreement to buy U.S. biotech firm Inhibrx for up to $2.2 billion, focusing on obtaining INBRX-101, an experimental treatment for Alpha-1 Antitrypsin Deficiency. |
| 2023 | Sanofi was ranked 89th in the Forbes Global 2000 list, highlighting its significant global business presence. |
| 2023 | Achieves a revenue of 43.07 billion euros, representing a significant financial milestone for the company. |
| 2023 | Acquisition of Provention Bio |
| November 2022 | Sanofi relocated to its new global headquarters at 46-48 Avenue de la Grande Armée in the 17th arrondissement of Paris. |
| April 2022 | Sanofi broke ground on a $638 million vaccine and enzymes production facility in Tuas, Singapore, targeted for completion in 2025. |
| 2021 | Multiple acquisitions including Kymab Ltd, Tidal Therapeutics, Translate Bio, Kadmon Corporation, Origimm Biotechnology, and Amunix Pharmaceuticals |
| September 2021 | Sanofi announced it would stop developing its mRNA COVID-19 vaccine, deciding not to proceed to Phase 3 trials due to being 'too late to reach the market'. |
| August 2021 | Sanofi announced the acquisition of Translate Bio and its mRNA vaccine technology for $3.2 billion. |
| June 2021 | Sanofi partnered with Capgemini, Orange & Generali to launch Future4care, an all-European start-up accelerator focused on digital health innovation. |
| 2020 | Acquisitions of Principia Biopharma and Kiadis Pharma |
| 2020 | Sanofi, partnering with GSK, signed a $2.1 billion deal with the US government's Operation Warp Speed to provide 100 million doses of COVID-19 vaccine. |
| June 2020 | Sanofi agreed to a potential $2 billion deal with Translate Bio, expanding an existing collaboration for COVID-19 treatments. |
| 2019 | Acquisition of Synthorx |
| January 2018 | Sanofi announced two major acquisitions: Bioverativ for $11.6 billion and Ablynx for €3.9 billion ($4.8 billion). |
| 2017 | Acquisitions of Protein Sciences and True North Therapeutics |
| July 2017 | Sanofi announced its intention to acquire Protein Sciences, a privately held Connecticut-based vaccines biotechnology company, for $650 million with potential additional $100 million in milestone achievements. |
| 2016 | Sold Merial to Boehringer Ingelheim |
| October 28 2015 | Sanofi voluntarily recalled Auvi-Q epinephrine auto-injection devices in the US and Canada due to potential inaccurate dosage delivery systems. |
| April 2 2015 | Olivier Brandicourt became the new CEO of Sanofi, replacing interim CEO Serge Weinberg. |
| October 2014 | Sanofi's board of directors fired US-resident chief executive Chris Viehbacher due to alleged lack of communication and poor strategy execution. |
| October 29 2014 | Health Canada granted Sanofi permission to resume BCG vaccine production after a two-year shutdown. |
| March 2014 | FDA issued a warning about potential cognitive adverse effects of PCSK9 inhibition, requiring neurocognitive testing in Phase III clinical trials. This impacted Sanofi's competition with Amgen and Pfizer for a PCSK9 inhibitor drug. |
| 2013 | FDA approved Kynamro (Mipomersen), an antisense drug for the orphan disease homozygous familial hypercholesterolemia, which was originally acquired by Genzyme in 2008. |
| 2013 | Sanofi announced a monoclonal antibody called sarilumab showed better efficacy than placebo in its first Phase III trial for rheumatoid arthritis, developed through collaboration with Regeneron Pharmaceuticals. |
| March 2013 | Apotex lost a jury trial in its $3.4 billion lawsuit against BMS and Sanofi for allegedly breaching a settlement agreement. |
| 2012 | Zaltrap (aflibercept combination) received approval for metastatic colorectal cancer treatment. |
| 2012 | Sanofi licensed and received FDA approval for Auvi-Q (Epinephrine autoinjector) for emergency treatment of life-threatening allergic reactions. |
| October 25 2012 | Sanofi reported a significant drop in third-quarter earnings, attributed to generic competitors impacting profits from its Eloxatin cancer treatment. |
| September 2012 | FDA approved Aubagio (Teriflunomide), a small molecule for multiple sclerosis. |
| April 2012 | The FDA discovered multiple sterility issues at the Toronto plant, including mold, nesting birds, and rusted electrical conduits, leading to the plant's closure. |
| February 2012 | Apotex paid approximately $442 million in damages and $108 million in interest for patent infringement to BMS/Sanofi. |
| January 2012 | Sanofi moved its head office to 54, Rue La Boétie in the 8th arrondissement of Paris, relocating from its previous office in the 13th arrondissement at 174 Avenue de France. |
| 2011 | Sanofi acquired Genzyme Corporation for around $20.1 billion, a biotechnology company specializing in treatments for orphan diseases, renal diseases, endocrinology, oncology, and biosurgery. |
| 2011 | A Sanofi Pasteur plant in Toronto, Ontario, Canada was flooded, causing mold problems and affecting BCG vaccine production. |
| 2011 | Concludes the Sanofi-Aventis corporate naming period. |
| 2011 | Eylea (aflibercept) received FDA approval for proliferative eye diseases. |
| November 2011 | Apotex lost its third patent appeal against BMS/Sanofi regarding clopidogrel. |
| May 6 2011 | Sanofi dropped the -Aventis suffix from its name after receiving approval at its annual general meeting, aiming to make the name easier to pronounce in countries like China. |
| 2010 | Sanofi acquired Nepentes Pharma for $130 million and BMP Sunstone Corporation for $520.6 million. |
| 2010 | Sanofi-Aventis purchased Chattem, acquiring over-the-counter brands like Allegra, IcyHot, Gold Bond, and Selsun Blue. |
| 2010 | US consumer healthcare company Chattem, Inc. was acquired for around $1.9 billion. |
| June 2010 | Sanofi signed a cooperation agreement with the Charité University of Berlin for collaborative research and development of medicines and therapies. |
| May 2010 | The Medley Farma acquisition was approved by Brazil's antitrust authorities. |
This contents of the box above is based on material from the Wikipedia article Sanofi, which is released under the Creative Commons Attribution-ShareAlike 4.0 International License.